Skip to main content
. 2022 Apr 14;12:864066. doi: 10.3389/fonc.2022.864066

Table 4.

The relationship between Epstein Barr virus detection in tumor using polymerase chain reaction (PCR) with the clinicopathological variables.

Variable EBV (PCR) (n=%)
(-) (+) p-value Estimate (OR/CI)
Age 38.4 ± 10.0 39.0 (32.0-47.0) 0.496 1.00 (-3.00-5.00)
Sex

  • Male

 14/35 (40.0) 59/143 (41.3) 0.892 0.95 (0.47-1.95)

  • Female

 21/35 (60.0) 84/143 (58.7)
HIV status

  • Positive

 25/35 (71.4) 114/143 (79.7) 0.288 1.37 (0.64-1.47)

  • Negative

 10/35 (28.6) 29/143 (20.3)
HIV Status Awareness

  • Aware HIV+

 22/25 (88.0) 107/114 (93.9) 0.386* 0.47 (0.12-1.82)

  • Unaware HIV+

 3/25 (12.0) 7/114 (6.1)
ART Uptake

  • Yes

 22/25 (88.0) 99/114 (86.8) >0.999* 1.11 (0.32-3.87)

  • No

 3/25 (12.0) 15/114 (13.2)
CD4 Count 290.0 (177.0-417.0) 199.0 (114.0 – 372.0) 0.211a -52.0 (-137.0-34.0)
CD4 Count category

  • <200

 8/23 (34.8) 50/101 (49.5) 0.250 0.54 (0.21-1.45)

  • >200

 15/23 (65.2) 51/101 (50.5)
Plasma HIV Viral load 0.0 (0.0 – 0.0) 0.0 (0.0 – 229.3) 0.022a 0.0 (0.0-128.0)
Plasma HIV Viral load (c)

  • <200

 14/15 (93.3) 49/70 (70.0) 0.101* 6.00 (0.96-66.4)

  • >200

 1/15 (6.7) 21/70 (30.0)
Diagnosis

  • Invasive OSSN

 27/35 (77.1) 105/143 (73.4) 0.653 1.22 (0.51-2.80)

  • Pre-invasive OSSN

 8/35 (22.9) 38/143 (26.6)
Preinvasive tumor grade

  • CIN I

 0/8 (0.0) 2/38 (5.3) 0.547# N/A

  • CIN II

 0/8 (0.0) 3/38 (7.9)

  • CIN III

 4/8 (50.0) 14/38 (36.8)

  • CIS

 4/8 (50.0) 19/38 (50.0)
Grouped Preinvasive tumor grade

  • CIN I and II

 0/8 (0.0) 5/38 (13.2) 0.569* N/A

  • CIN III and CIS

 8/8 (100.0) 33/38 (86.8)
Invasive tumor subtype

  • Keratinizing SCC

 25/27 (92.6) 98/105 (93.3) 0.742 N/A

  • Basaloid SCC

 1/27 (3.7) 5/105 (4.8)

  • Spindle SCC

 1/27 (3.7) 2/105 (1.9)
Invasive tumor grouped

  • Keratinizing

 25/27 (92.6) 98/105 (93.3) 0.892 0.89 (0.18-4.47)

  • Non-keratinizing

 2/27 (7.4) 7/105 (6.7)
Grade of invasive tumor

  • Well, differentiated

 2/27 (7.4) 15/105 (14.3) 0.492 N/A

  • Moderately differentiated

 23/27 (85.2) 82/105 (78.1)

  • Poorly differentiated

 2/27 (7.4) 8/105 (7.6)
AJCC Stage

  • T1

 5/27 (18.5) 9/105 (8.6) 0.285 N/A

  • T2

 8/27 (29.6) 28/105 (26.7)

  • T3

 12/27 (44.4) 67/105 (63.8)

  • T4

 2/27 (7.4) 1/105 (0.9)
Grouped AJCC Stage

  • T1/T2

 13/27 (48.1) 37/105 (35.2) 0.217 1.71 (0.70-4.09)

  • T3/T4

 14/27 (52.9) 68/105 (64.8)

Non-parametric: Confidence interval did use Independent-Samples Hodges-Lehman Median Difference; aMann-Whitney; *Fishers exact test; #Chisquare trend test.

N/A, Not applicable.